European Journal of Cancer
Volume 39, Issue 13 , Pages 1818-1827 , September 2003

Current research and treatment for epithelial ovarian cancer A Position Paper from the Helene Harris Memorial Trust

  • F. Balkwill

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-20-7882-6106; fax: +44-20-7882-6110
    • ,
  • R.C. Bast Jr.

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • J. Berek

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • G. Chenevix-Trench

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • M. Gore

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • T. Hamilton

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • I. Jacobs

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • G. Mills

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • R. Souhami

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • N. Urban

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • S. Ursulic

      Affiliations

    • Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • J. Smyth

      Affiliations

    • Cancer Research UK, University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, UK

Received 5 June 2003 ,Accepted 5 June 2003.

References 

  1. Bayani J, Brenton JD, Macgregor PF, et al.  Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 2002;62:3466–3476
  2. Gray JW, Suzuki S, Kuo WL, et al.  Specific keynote (genome copy number abnormalities in ovarian cancer). Gynecol. Oncol. 2003;88:S16–21,S22-4
  3. Shi H, Wei SH, Leu Y-W, et al.  Triple analysis of the cancer epigenome (an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation). Cancer Res. 2003;63:2164–2171
  4. Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV. Differential expression of members of the tumor necrosis factor a-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res. 2001;61:7179–7183
  5. Petricoin III EF, Ardekani AM, Hitt BA, et al.  Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  6. Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium (changes with neoplastic progression and with a family history of ovarian cancer). Int. J. Cancer. 1996;69:429–436
  7. Barakat RR, Sabbatini P, Bhaskaran D, et al.  Intraperitoneal chemotherapy for ovarian carcinoma (results of long-term follow-up). Clin. Oncol. 2002;20:694–698
  8. Werness BA, Ramus SJ, Whittemore AS, et al.  Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum. Pathol. 2000;31:1420–1424
  9. Thomas NA, Neville PJ, Baxter SW, Campbell IG. Genetic analysis of benign ovarian tumors. Int. J. Cancer. 2003;105:499–505
  10. Denison SR, Becker NA, Ferber MJ, et al.  Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer. Genes, Chromosomes Cancer. 2002;34:406–415
  11. Paige AJW, Taylor KJ, Taylor C, et al.  WWOX (a candidate tumor suppressor gene involved in multiple tumor types). PNAS. 2001;98:11417–11422
  12. Sellar GC, Watt KP, Rabiasz GJ, et al.  The IgLON family member OPCML (OBCAM) at 11q25 is epigenetically inactivated and demonstrates tumor suppressor function in epithelial ovarian cancer. Nat Genet. 2003;
  13. Tutt ANJ, van Oostrom CTM, Ross GM, van Steeg H, Ashworth A. Disruption of Brca2 increases the spontaneous mutation rate in vivo (synergism with ionizing radiation). EMBO Rep. 2002;3:255–260
  14. Shridhar V, Lee J, Pandita A, et al.  Genetic analysis of early versus late-stage ovarian tumours 1. Cancer Res. 2001;61:5895–5904
  15. Lu KH, Patterson A, Atkinson EN, et al.  Selection of potential markers for epithelial ovarian cancer with gene expression array analysis and recursive descent partition analysis. Proc Am Assoc Cancer Res. 2003;44:573
  16. Testa JR, Getts LA, Salazar H, et al.  Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 1994;54:2778–2784
  17. Roby KF, Taylor CC, Sweetwood JP, et al.  Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–591
  18. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro. 1984;20:743–755
  19. Liu J, Yang JA, Thompson N, et al.  Malignant transformation of human ovarian surface epithelial cell through genetic modifications. Proc. Am. Assoc. Cancer Res. 2002;43:23
  20. Liu J, Patterson A, Thompson JA, Mills G, Gray J, Bast RC. Transformation targets of human ovarian surface epithelial cells by oncogenic H-rasV12 or K-ras V12 revealed by gene expression array analysis. Proc. Am. Assoc. Cancer Res. 2003;44:270
  21. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1:53–62
  22. Orsulic S. An RCAS-TVA-based approach to designer mouse models. Mammalian Genome. 2002;13:543–547
  23. Connolly DC, Bao R, Nitkin AY, et al.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003;636:1389–1397
  24. Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growth orthotopically. Clin Cancer Res [in press].
  25. Balkwill F. Chemokine biology in cancer. Semin Immunol. 2003;15:49–55
  26. Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br. J. Cancer. 2001;85:891–897
  27. Scotton CJ, Wilson JL, Scott K, et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002;62:5930–5938
  28. Hu Y-L, Tee M-K, Goetzl EJ, et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 2001;93:762–768
  29. Markman M, Liu PY, Wilczynski S, et al. Phase 3 randomized trial of 12 versus 3 months single agent paclitaxel in patients with advanced ovarian cancer who attained clinically-defined complete response to platinum/paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol [in press].
  30. Wall L, Burke F, Barton C, Smyth J, Balkwill F. Interferon gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res [in press].
  31. Szlosarek P, Balkwill F. Tumour necrosis factor-a: a potential target in the therapy of solid tumors. Lancet Oncol [in press].
  32. Bowman A, Gabra H, Langdon SP, et al.  CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer (identification of an endocrine-sensitive subgroup). Clin. Cancer Res. 2002;8:2233–2239
  33. Drucker, B.J., Marincola, F.M., Siao, D.Y., Donlon, T.A., Bangs, C.D., Holder, W.D., A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice, In Vitro Cell Dev. Biol. 24, 1988, 1179–1187.
  34. Verweij J, van Oostrom A, Blay J-Y et al., Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC soft tissue and bone sarcoma group phase II study. Eur J Cancer [In press].
  35. Disis ML, Gooley TA, Rinn K, et al.  Generation of T cell immunity to the HER-2/neu protein after active immunization with a HER-2/;neu peptide based vaccine. J. Clin. Oncol. 2002;20:2624–2632
  36. Knutson KL, Disis ML. Expansion of HER-2/neu specific T cells ex vivo following immunization with a HER-2/neu peptide based vaccine. Clin. Breast Cancer. 2001;2:73–79
  37. Knutson KL, Disis ML. Diversity of the T cell population responding to a dominant HLA-A2 epitope of HER-2/neu in an ovarian cancer patient. Human Immunol. 2002;63:547–557
  38. Chang K, Pastan I. Molecular cloning of messothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. PNAS. 1996;93:136–140
  39. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family (structure, function, and association to disease). Endocrine Rev. 2001;22:184–204
  40. Diamandis EP, Yousef GM. Human tissue kallkreins (a family of new cancer biomarkers). Clin. Chem. 2002;48:1198–1205
  41. Kim J-H, Skates SJ, Uede T, et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287:1671–1679
  42. Pepe MS, Longton G, Anderson G, Schummer M. Selecting differentially expressed genes from microarray experiments. Biometrics [in press].
  43. Schummer M, Ng WG, Bumgarner RE, et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes expressed in ovarian carcinomas. Gene. 1999;238:375–385
  44. Scholler N, Fu N, Yang Y, et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. PNAS. 1999;96:11531–11536
  45. Skates SJ, Xu FJ, Yu JH, et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76:2004–2010
  46. Skates S, Pauler DK. Screening based on risk of cancer calculation from Bayesian hierarchical change-point models of longitudinal markers. JASA [in press].
  47. McIntosh MW, Urban N. A parametric empirical bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003;2003:27–40
  48. Zhang Z, Barnhill SD, Zhang H, et al.  Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 1999;73:56–61
  49. McIntosh MW, Pepe M. Combining several screening tests (optimality of the risk score). Biometrics. 2002;58:657–664
  50. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer. 1992;50:373–381

☆ Complete abstracts for the meeting and full addresses for the other authors (who chaired the individual sessions) are published on the HHMT website (). The names in bold refer to the speakers at the meeting and can also be found on the HHMT website.

☆☆ The Helene Harris Memorial Trust was founded in 1986 by John Harris and his family, in memory of John's wife Helene who died aged 48 years of ovarian cancer. The HHMT promotes and funds dialogue, debate and forums to advance research, diagnosis and treatment in the field of ovarian cancer (www.hhmt.org). The HHMT is collating information for a world-wide database to locate all researchers and clinicians in the field of ovarian cancer. Please send details to database@hhmt.org.

PII: S0959-8049(03)00511-2

doi: 10.1016/S0959-8049(03)00511-2

European Journal of Cancer
Volume 39, Issue 13 , Pages 1818-1827 , September 2003

Article Tools